{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:08:47Z","timestamp":1789171727953,"version":"build-2803163510"},"reference-count":48,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Cancer"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Despite advances in radiation techniques, radiation cystitis (RC) remains a significant cause of morbidity from pelvic radiotherapy, which may affect patients\u2019 quality of life (QoL). The pathophysiology of RC is not well understood, which limits the development of effective treatments.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n The Radiotoxicity Bladder Biomarkers study aims to investigate the correlation between blood and urinary biomarkers and the intensity of acute RC symptoms and QoL in patients undergoing localized prostate cancer radiotherapy.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This study included patients with low- or intermediate-risk localized prostate cancer who were eligible for localized radiotherapy. Blood and urinary biomarkers were analyzed before radiotherapy was initiated and at weeks 4 and 12 of radiation therapy. Patients completed questionnaires related to RC symptoms and QoL (International Prostate Symptom Score and Functional Assessment of Cancer Therapy-Prostate [FACT-P]) using a digital remote monitoring platform. The information was processed by means of an algorithm, which classified patients according to the severity of symptoms and adverse events reported. Levels of blood and urinary biomarkers were tested with the severity of acute RC symptoms and patient-reported QoL.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 401 adverse events questionnaires were collected over the duration of this study from 20 patients. The most frequently reported adverse events at week 4 were pollakiuria, constipation, and diarrhea. In comparison with baseline, the mean FACT-P score decreased at week 4. A significant increase in the proportion of M2 phenotype cells (CD206+, CD163+, CD204+) at W12 compared to W0 was observed. An increase in serum and urine levels of macrophage colony-stimulating factor (M-CSF), hepatocyte growth factor, and macrophagic inflammatory protein was observed at week 12 compared to baseline levels. Baseline serum and urine M-CSF concentrations showed a significant negative correlation with FACT-P scores at weeks 4 and 12 (\n r<\/jats:italic>\n =\u22120.65,\n P<\/jats:italic>\n =.04, and\n r<\/jats:italic>\n =\u22120.76,\n P<\/jats:italic>\n =.02, respectively).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The Radiotoxicity Bladder Biomarkers study is the first to explore the overexpression of inflammatory proteins in blood and urine of patients with symptoms of acute RC. These preliminary findings suggest that serum and urine levels of hepatocyte growth factor, M-CSF, and macrophagic inflammatory protein, as well as macrophage polarization, are mobilized after prostate radiotherapy. The elevated M-CSF levels in serum and urine at baseline were associated with the deterioration of QoL during radiotherapy. The results of this study may help to develop mitigation strategies to limit radiation damage to the bladder.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/48225","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T08:53:30Z","timestamp":1719219210000},"page":"e48225-e48225","source":"Crossref","is-referenced-by-count":3,"title":["Correlation Between Electronic Patient-Reported Outcomes and Biological Markers of Key Parameters in Acute Radiation Cystitis Among Patients With Prostate Cancer (RABBIO): Prospective Observational Study"],"prefix":"10.2196","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-349X","authenticated-orcid":false,"given":"Carole","family":"Helissey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6581-3369","authenticated-orcid":false,"given":"Sophie","family":"Cavallero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6208-1147","authenticated-orcid":false,"given":"Nathalie","family":"Guitard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3809-2516","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Thery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7346-5883","authenticated-orcid":false,"given":"Charles","family":"Parnot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2513-4721","authenticated-orcid":false,"given":"Antoine","family":"Schernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-2948","authenticated-orcid":false,"given":"Imen","family":"Aissa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6532-5338","authenticated-orcid":false,"given":"Florent","family":"Raffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6929-2889","authenticated-orcid":false,"given":"Christine","family":"Le Coz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3668-3168","authenticated-orcid":false,"given":"Stanislas","family":"Mondot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7018-9770","authenticated-orcid":false,"given":"Christos","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2150-4024","authenticated-orcid":false,"given":"Karim","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0882-2167","authenticated-orcid":false,"given":"Emmanuelle","family":"Malaurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4785-3409","authenticated-orcid":false,"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0119-3695","authenticated-orcid":false,"given":"Cyrus","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-6122","authenticated-orcid":false,"given":"Sabine","family":"Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"R1","unstructured":"Le cancer de la prostate - les cancers les plus fr\u00e9quents. Intitut National du Cancer. URL: https:\/\/www.e-cancer.fr\/Professionnels-de-sante\/Les-chiffres-du-cancer-en-France\/Epidemiologie-des-cancers\/Les-cancers-les-plus-frequents\/Cancer-de-la-prostate [Accessed 9-11-2024]"},{"issue":"1","key":"R2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","journal-title":"CA A Cancer J Clin"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.2147\/RRU.S243088","article-title":"The impact of prostate cancer treatment on quality of life: a narrative review with a focus on randomized data","volume":"12","author":"Taylor","journal-title":"Res Rep Urol"},{"issue":"10","key":"R4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/nrurol.2013.185","article-title":"Evolution of advanced technologies in prostate cancer radiotherapy","volume":"10","author":"Zaorsky","journal-title":"Nat Rev Urol"},{"issue":"3","key":"R5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00345-019-02661-6","article-title":"Evolution of definitive external beam radiation therapy in the treatment of prostate cancer","volume":"38","author":"Daly","journal-title":"World J Urol"},{"issue":"1","key":"R6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.hoc.2019.08.017","article-title":"Radiation therapy for prostate cancer","volume":"34","author":"Kamran","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"R7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/1754-9485.12213","article-title":"Stereotactic body radiotherapy for primary prostate cancer: a systematic review","volume":"58","author":"Tan","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"7","key":"R8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrurol.2017.76","article-title":"The evolution of brachytherapy for prostate cancer","volume":"14","author":"Zaorsky","journal-title":"Nat Rev Urol"},{"issue":"8","key":"R9","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial","volume":"17","author":"Incrocci","journal-title":"Lancet Oncol"},{"issue":"1","key":"R10","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010021","article-title":"Chronic inflammation and radiation-induced cystitis: molecular background and therapeutic perspectives","volume":"10","author":"Helissey","journal-title":"Cells"},{"issue":"2","key":"R11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11608-010-0302-5","article-title":"Cystite radique","volume":"5","author":"Rigaud","journal-title":"Pelv Perineol"},{"issue":"4","key":"R12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"R13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.5489\/cuaj.5788","article-title":"Canadian Urological Association best practice report: diagnosis and management of radiation-induced hemorrhagic cystitis","volume":"13","author":"Goucher","journal-title":"Can Urol Assoc J"},{"issue":"10","key":"R14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241388","article-title":"Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine","volume":"15","author":"Zwaans","journal-title":"PLoS One"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2017.11.002","article-title":"The role of macrophage phenotype in regulating the response to radiation therapy","volume":"191","author":"Shi","journal-title":"Transl Res"},{"issue":"6-7","key":"R16","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.canrad.2020.06.007","article-title":"Treatment of radiation-induced late effects: what\u2019s new?","volume":"24","author":"Chargari","journal-title":"Cancer Radiot"},{"issue":"3","key":"R17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/path.4299","article-title":"Responses to ionizing radiation mediated by inflammatory mechanisms","volume":"232","author":"Mukherjee","journal-title":"J Pathol"},{"issue":"10","key":"R18","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1494488","article-title":"Macrophages in radiation injury: a new therapeutic target","volume":"7","author":"Meziani","journal-title":"Oncoimmunology"},{"issue":"5","key":"R19","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.ijrobp.2014.01.002","article-title":"Relationship between radiation-induced apoptosis of T lymphocytes and chronic toxicity in patients with prostate cancer treated by radiation therapy: a prospective study","volume":"88","author":"Foro","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"Suppl 1","key":"R20","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2020.61.S1.S8","article-title":"Advances in urinary biomarker discovery in urological research","volume":"61","author":"Kim","journal-title":"Investig Clin Urol"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2018.02.039","article-title":"Elevated urine levels of macrophage migration inhibitory factor in inflammatory bladder conditions: a potential biomarker for a subgroup of interstitial cystitis\/bladder pain syndrome patients","volume":"116","author":"Vera","journal-title":"Urology"},{"issue":"9","key":"R22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.clon.2016.04.041","article-title":"Acute and late genitourinary toxicity after 72 Gy of conventionally fractionated conformal radiotherapy for localised prostate cancer: impact of individual and clinical parameters","volume":"28","author":"Stankovic","journal-title":"Clin Oncol"},{"issue":"1","key":"R23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10255-6","article-title":"Circulating levels of IL-6 and TGF-\u03b21 in patients with prostate cancer undergoing radiotherapy: associations with acute radiotoxicity and fatigue symptoms","volume":"22","author":"Kop\u010dali\u0107","journal-title":"BMC Cancer"},{"issue":"2","key":"R24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/nur.20247","article-title":"Considerations in determining sample size for pilot studies","volume":"31","author":"Hertzog","journal-title":"Res Nurs Health"},{"issue":"3","key":"R25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1177\/0962280216651022","article-title":"Pilot studies in clinical research","volume":"25","author":"Julious","journal-title":"Stat Methods Med Res"},{"issue":"6","key":"R26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066106","article-title":"The chemokine CCL3 promotes experimental liver fibrosis in mice","volume":"8","author":"Heinrichs","journal-title":"PLoS One"},{"key":"R27","unstructured":"The R Project for Statistical Computing. r-project.org. URL: https:\/\/www.r-project.org\/ [Accessed 13-11-2024]"},{"issue":"17","key":"R28","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","journal-title":"N Engl J Med"},{"issue":"3","key":"R29","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1470-2045(14)70482-6","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial","volume":"16","author":"Aluwini","journal-title":"Lancet Oncol"},{"issue":"8","key":"R30","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","journal-title":"Lancet Oncol"},{"issue":"8","key":"R31","first-page":"530","volume":"14","author":"Pakhomov","journal-title":"Am J Manag Care"},{"issue":"12","key":"R32","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","journal-title":"N Engl J Med"},{"issue":"2","key":"R33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","journal-title":"J Pathol"},{"issue":"12","key":"R34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121747","article-title":"Is the macrophage phenotype determinant for fibrosis development?","volume":"9","author":"Lis-L\u00f3pez","journal-title":"Biomedicines"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.803037","article-title":"Macrophage polarization and its role in liver disease","volume":"12","author":"Wang","journal-title":"Front Immunol"},{"issue":"2","key":"R36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/toxsci\/kfy309","article-title":"Role of macrophages in acute lung injury and chronic fibrosis induced by pulmonary toxicants","volume":"168","author":"Laskin","journal-title":"Toxicol Sci"},{"issue":"1","key":"R37","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2119\/molmed.2012.00131","article-title":"MyD88 signaling pathway is involved in renal fibrosis by favoring a TH2 immune response and activating alternative M2 macrophages","volume":"18","author":"Braga","journal-title":"Mol Med"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00430","article-title":"Hepatic localization of macrophage phenotypes during fibrogenesis and resolution of fibrosis in mice and humans","volume":"5","author":"Beljaars","journal-title":"Front Immunol"},{"issue":"1","key":"R39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41420-023-01310-7","article-title":"Regulatory T cell and macrophage crosstalk in acute lung injury: future perspectives","volume":"9","author":"Guan","journal-title":"Cell Death Discov"},{"issue":"4","key":"R40","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/path.5632","article-title":"Macrophage-stroma interactions in fibrosis: biochemical, biophysical, and cellular perspectives","volume":"254","author":"Vasse","journal-title":"J Pathol"},{"issue":"2","key":"R41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41577-021-00568-1","article-title":"Immunomodulation by radiotherapy in tumour control and normal tissue toxicity","volume":"22","author":"Cytlak","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"R42","doi-asserted-by":"publisher","first-page":"39572","DOI":"10.1038\/srep39572","article-title":"Loss of miR-140 is a key risk factor for radiation-induced lung fibrosis through reprogramming fibroblasts and macrophages","volume":"6","author":"Duru","journal-title":"Sci Rep"},{"issue":"3","key":"R43","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02120-2017","article-title":"CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages","volume":"51","author":"Meziani","journal-title":"Eur Respir J"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.627927","article-title":"Activated hepatic stellate cells induce infiltration and formation of CD163+ macrophages via CCL2\/CCR2 pathway","volume":"8","author":"Xi","journal-title":"Front Med"},{"issue":"6","key":"R45","doi-asserted-by":"publisher","first-page":"588","DOI":"10.2183\/pjab.86.588","article-title":"The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine","volume":"86","author":"Nakamura","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7696-8_27","article-title":"Macrophage inflammatory protein-1 alpha (MIP-1 alpha)\/CCL3: as a biomarker","author":"Bhavsar","journal-title":"Gen Methods Biomark Res Appl"},{"issue":"1","key":"R47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1165\/rcmb.2010-0265OC","article-title":"The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis","volume":"45","author":"Yang","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"R48","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1164\/rccm.200609-1279OC","article-title":"Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis","volume":"176","author":"Baran","journal-title":"Am J Respir Crit Care Med"}],"container-title":["JMIR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cancer.jmir.org\/2024\/1\/e48225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:28:45Z","timestamp":1782840525000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancer.jmir.org\/2024\/1\/e48225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":48,"URL":"https:\/\/doi.org\/10.2196\/48225","relation":{},"ISSN":["2369-1999"],"issn-type":[{"value":"2369-1999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"article-number":"v10i1e48225"}}